William Grossman

TL;DR: Single-agent atezolizumab was well tolerated and provided durable clinical benefit in patients with mTNBC with stable or responding disease and in earlier lines of treatment.

TL;DR: It is hypothesized that the combination of atezolizumab (atezo; anti–PD-L1) + bev results in a greater clinical benefit due to the additional immunomodulatory effects of bev, which create a more favorable tumor microenvironment that potentiates the efficacy ofatezo.

TL;DR: The preliminary findings suggest that biomarkers, including peripheral CD4+ T cells and hypermutated tumor status, may help guide selection of patients with recurrent glioblastoma who might receive most benefit from atezolizumab therapy, supporting further atzolizUMab combination studies in gliOBlastoma.

TL;DR: In this heavily pre-treated advanced HNC cohort of the phase Ia PCD4989g clinical trial, atezolizumab had a tolerable safety profile and encouraging activity, with responses observed regardless of HPV status and PD-L1 expression level.

TL;DR: All abstracts presented at American Society of Clinical Oncology annual meetings from 2010 to 2017 for FiH trials enrolling at least 100 patients are reviewed to identify seamless trials and recommend protocols of sufficient rigor to support accelerated approval.